llms.txt
Compare with other sites' llms.txt files →# CancerNetwork
> CancerNetwork - Healthcare Publication
- Base URL: https://www.cancernetwork.com
- Generated: 2026-11-09T12:29:44.400Z
- Content updates: multiple times daily
## Content Access for AI Agents
This site supports content negotiation for AI/LLM consumption. Request any article URL with an appropriate Accept header to receive structured content instead of HTML.
**Supported content types:**
- `text/markdown` — Clean Markdown with YAML frontmatter
- `text/plain` — Plain text (same as Markdown)
- `text/html` — Default HTML response
**Example request:**
```
curl -H "Accept: text/markdown" https://www.cancernetwork.com/view/article-slug
```
**YAML frontmatter schema** (returned with every Markdown response):
| Field | Type | Description |
|-------|------|-------------|
| `title` | string | Article headline |
| `description` | string | Summary/excerpt (max 300 chars) |
| `url` | string | Canonical article URL |
| `canonical_url` | string | Canonical URL if different from `url` |
| `published` | ISO 8601 | Original publication date |
| `modified` | ISO 8601 | Last modification date |
| `authors` | string[] | Author display names |
| `content_type` | string | Content category (e.g., "News", "Clinical") |
| `categories` | string[] | Taxonomy categories |
| `tags` | string[] | SEO tags |
| `image` | string | Featured image URL |
| `publisher` | string | Publication/site name |
**Discovery headers** (included on all responses):
- `Link: <https://www.cancernetwork.com/llms.txt>; rel="llms"` — RFC 8288 link to this file
- `X-Llms-Txt: https://www.cancernetwork.com/llms.txt` — Explicit discovery header
## Usage Policy
- Robots policy: [https://www.cancernetwork.com/robots.txt](https://www.cancernetwork.com/robots.txt)
- Cache behavior: responses are cached for ~5 minutes (max-age=300, stale-while-revalidate=329)
- Rate guidance: prefer RSS and sitemap feeds over crawling individual pages
- Attribution: All content © MJH Life Sciences. Include source URLs when citing.
## Content Categories
- [Around the Practice](https://www.cancernetwork.com/around-the-practice)
- [Between the Lines](https://www.cancernetwork.com/between-the-lines)
- [Breaking Barriers](https://www.cancernetwork.com/breaking-barriers)
- [Clinical](https://www.cancernetwork.com/clinical)
- [Clinical Consult](https://www.cancernetwork.com/clinical-consult)
- [Conference](https://www.cancernetwork.com/conference)
- [Face-Off](https://www.cancernetwork.com/face-off)
- [From All Angles](https://www.cancernetwork.com/from-all-angles)
- [Frontline Forum](https://www.cancernetwork.com/frontline-forum)
- [Global Bulletin](https://www.cancernetwork.com/global-bulletin)
- [Hero](https://www.cancernetwork.com/hero)
- [Integrative Care](https://www.cancernetwork.com/integrative-care)
- [Media](https://www.cancernetwork.com/media)
- [Meeting of the Minds](https://www.cancernetwork.com/meeting-of-the-minds)
- [Men's Health](https://www.cancernetwork.com/mens-health)
- [News](https://www.cancernetwork.com/news)
- [OncView](https://www.cancernetwork.com/k-cast)
- [Podcasts](https://www.cancernetwork.com/podcasts)
- [Publications](https://www.cancernetwork.com/journals)
- [Quizzes](https://www.cancernetwork.com/resources/quizzes)
- [Readout 360](https://www.cancernetwork.com/readout-360)
- [Resources](https://www.cancernetwork.com/resources)
- [Roles](https://www.cancernetwork.com/roles)
- [The Bispecifics Network](https://www.cancernetwork.com/the-bispecific-network)
- [Training Academy](https://www.cancernetwork.com/training-academy)
- [Treatment Algorithms with the Oncology Brothers](https://www.cancernetwork.com/treatment-algorithms-with-the-oncology-brothers)
- [Tumor Board Series](https://www.cancernetwork.com/tumor-board-series)
- [Video Series](https://www.cancernetwork.com/video-series)
- [Videos](https://www.cancernetwork.com/videos)
- [Webinars](https://www.cancernetwork.com/webinars)
- [Year in Review](https://www.cancernetwork.com/year-in-review)
## Featured Content
- [Azacitidine Plus Ruxolitinib Shows Durable Responses in Myelofibrosis](https://www.cancernetwork.com/view/azacitidine-plus-ruxolitinib-shows-durable-responses-in-myelofibrosis): In a phase 2 study, azacitidine plus ruxolitinib produced a 78% objective response rate in patients with chronic phase myelofibrosis.
- [Defining the Optimal Window for Cytoreductive SABR in Metastatic Kidney Cancer](https://www.cancernetwork.com/view/defining-the-optimal-window-for-cytoreductive-sabr-in-metastatic-kidney-cancer): Shankar Siva, MBBS, PhD, FRANZCR, discussed when to consider cytoreductive SABR in patients with metastatic kidney cancer responding to systemic thera...
- [Closing the HCC Surveillance Gap in MASLD Without Cirrhosis](https://www.cancernetwork.com/view/closing-the-hcc-surveillance-gap-in-masld-without-cirrhosis): At The Liver Meeting 2026, Daniel Q. Huang, MBBS, PhD, explained why cirrhosis-based HCC surveillance misses many patients with MASLD and how to find...
- [Weighing HCC Surveillance for Patients With MASLD and F3 Fibrosis](https://www.cancernetwork.com/view/weighing-hcc-surveillance-for-patients-with-masld-and-f3-fibrosis): At The Liver Meeting 2026, Hashem B. El-Serag, MD, MPH, discussed when patients with MASLD and F3 fibrosis may merit HCC surveillance.
- [Closing the Gap Between Tumor Board Recommendations and Liver Cancer Care](https://www.cancernetwork.com/view/closing-the-gap-between-tumor-board-recommendations-and-liver-cancer-care): At The Liver Meeting 2026, Pierre Gholam, MD, explained why liver tumor board plans often break down at implementation and how navigators can help.
- [Rethinking Surveillance and Multidisciplinary Care in MASLD-Related HCC](https://www.cancernetwork.com/view/rethinking-surveillance-and-multidisciplinary-care-in-masld-related-hcc): Surveillance guidelines limited to cirrhosis may miss up to a third of patients with MASLD-related HCC, according to Daniel Q. Huang, MBBS, PhD.
- [Building Systems to Catch Liver and Other Cancers in Patients With MASLD](https://www.cancernetwork.com/view/building-systems-to-catch-liver-and-other-cancers-in-patients-with-masld): Hashem B. El-Serag, MD, MPH, discussed fibrosis-based HCC surveillance, ultrasound limits, chemoprevention, and alcohol screening for patients with MA...
- [Eliciting Patient Preferences to Guide HCC Treatment Decisions](https://www.cancernetwork.com/view/eliciting-patient-preferences-to-guide-hcc-treatment-decisions): At The Liver Meeting® 2026, Andrew Moon, MD, MPH, discussed research revealing gaps between clinician and patient priorities in HCC treatment choice.
- [Changing Mindsets and Removing Guilt Surrounding Lung Cancer Diagnoses](https://www.cancernetwork.com/view/changing-mindsets-and-removing-guilt-surrounding-lung-cancer-diagnoses): Chinmay Jani, MD, describes how he counsels patients with and without a smoking history on a lung cancer diagnosis.
- [Rusfertide Improves Hematocrit Control vs Placebo in Polycythemia Vera](https://www.cancernetwork.com/view/rusfertide-improves-hematocrit-control-vs-placebo-in-polycythemia-vera): In the VERIFY trial, rusfertide produced a clinical response in 77% of phlebotomy-dependent patients with polycythemia vera receiving standard-of-care...
## Feeds and Indexes
- [RSS Feed](https://www.cancernetwork.com/rss.xml): Latest articles in XML syndication format
- [Sitemap](https://www.cancernetwork.com/sitemap.xml): Complete URL index for all published pages
- [News Sitemap](https://www.cancernetwork.com/sitemap-news.xml): Recent articles optimized for news indexing
- [Authors Directory](https://www.cancernetwork.com/authors): Browse all contributors and their published work